Q3 Earnings: Big Pharma Keeps The Good Times Rolling While Hiking Prices
Top Brand Name Drug Makers Best Earnings Forecasts While Evading Accountability
And that’s a wrap! Three weeks of earnings calls have proven, yet again, that Big Pharma’s top concern is padding their bottom line and keeping a profit gravy train running – not helping patients.
This quarter, CSRxP tracked earnings reports from 12 of the world’s largest brand name drug makers – AbbVie, Bristol-Myers Squibb, Sanofi, GlaxoSmithKline, Amgen, Pfizer, Merck, AstraZeneca, Eli Lilly, Johnson & Johnson, Roche and Novartis. Every single one of these Big Pharma giants beat earnings expectations after continuing to increase prices on struggling Americans.
These results were not surprising considering Big Pharma’s long-standing record of price-gouging patients and fighting to maintain the status quo, despite the fact that one-in-four Americans are unable to afford their prescription medications.
Read CSRxP’s “Big Pharma Earnings Watch” Blog on AbbVie HERE.
Read CSRxP’s “Big Pharma Earnings Watch” Blog on Bristol-Myers Squibb and Sanofi HERE.
Read CSRxP’s “Big Pharma Earnings Watch” Blog on GlaxoSmithKline and Amgen HERE.
Read CSRxP’s “Big Pharma Earnings Watch” Blog on Merck and Pfizer HERE.
Read CSRxP’s “Big Pharma Earnings Watch” Blog on Eli Lilly HERE.
Read CSRxP’s “Big Pharma Earnings Watch” Blog on AstraZeneca HERE.
Read CSRxP’s “Big Pharma Earnings Watch” Blog on Johnson & Johnson, Roche and Novartis HERE.
###